Hematology/Oncology

Top Story

VIDEO: Progress in MRD testing poised to further improve patient outcomes in myeloma

May 3, 2016

C. Ola Landgren, MD, PhD, chief of the myeloma service at the Memorial Sloan Kettering Cancer Center in New York City, discusses the advances in outcomes in multiple myeloma, with specific focus on developments in minimal residual disease testing.

Meeting News CoverageVideo

VIDEO: Entrectinib safely, effectively treats gene-mutated cancers

May 2, 2016
NEW ORLEANS — Alexander Drilon, MD, assistant attending physician with the developmental therapeutics clinic and thoracic oncology service at Memorial Sloan…

Indiana University Simon Cancer Center yoga program eases stress associated with diagnosis, treatment

May 2, 2016
Yoga therapy is an integrative medicine technique that supplements the traditional treatment regimens patients with cancer undergo.A patient’s quality of life may…
In the Journals

Endoscopic biopsy, EUS inadequate for detecting residual esophageal cancer after neoadjuvant chemoradiotherapy

May 2, 2016
Endoscopic biopsy and endoscopic ultrasound did not perform with sufficient accuracy in detecting pathologic complete response in patients with esophageal cancer after…
In the Journals

Blinatumomab appears safe, effective for heavily pretreated DLBCL

May 2, 2016
Blinatumomab monotherapy appeared effective for the treatment of heavily pretreated relapsed and refractory diffuse large B-cell lymphoma, according to the results of a…
More News Headlines »
CME

The Patient with Lymphadenopathy

No commercial support for this activity.

Castleman’s disease is a rare lymphoproliferative disorder that is characterized by enlargement of 1 (unicentric) or…
More »
Video
Meeting News Coverage

VIDEO: Entrectinib safely, effectively treats gene-mutated cancers

May 2, 2016
More »
Featured
At Issue: Multiple Myeloma Resource Center

At Issue: Multiple Myeloma Resource Center

CME

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease…
More »
Current Issues
View the Current Issue
HemOnc Today